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Abstract
Endoscopic retrograde pancreatography (ERP) is 
an accurate imaging modality in the diagnosis of 
pancreatobiliary diseases. However, its use has 
been substantially reduced due to the invasiveness 
of procedure, the risk of complications and the 
widespread availability of non-invasive cross-section 
imaging techniques (computed tomography, magnetic 
resonance imaging, and endoscopic ultrasound). Since 
the introduction of endoscopic sphincterotomy, ERP 
has transformed from diagnostic method to an almost 
exclusively therapeutic procedure. Pancreatic duct 
injection substantially increased the risk of post-ERP 
pancreatitis (1.6%-15.7%); therefore, according to 
international guidelines ERP is recommended only in 
cases where biliary intervention is required. However, 
the role of ERP in the management of pancreatic 
diseases is currently not clearly defined, but in some 
cases the filling of pancreatic duct may provide essential 
information complementing the results of non-invasive 
imaging techniques. The aim of this publication is to 
systematically summarize the literature dealing with 
the diagnostic yield of ERP. We would like to define 
the precise indications of ERP and overview a diag-
nostic protocol of pancreatic diseases depending on 
international guidelines and the opinion of Hungarian 
experts, because it may improve the diagnostic acc-
uracy, minimize of burden of patients and reduce the 
risk of procedure related complications.
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Core tip: Since the development and widespread 
availability of non-invasive imaging techniques the 
importance of diagnostic endoscopic pancreatography 
(ERP) has substantially reduced. However, in some 
complicated cases or during pancreatic interventional 
endoscopic procedures such as minor papilla sphin-
cterotomy, pancreatic sphincterotomy, pancreatic stent 
implantation, ERP may provide essential information. 
This article seeks to summarize the results of previous 
studies and recommendations of international guidelines 
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to define the diagnostic yield and correct indications of 
ERP.
Bor R, Madácsy L, Fábián A, Szepes A, Szepes Z. Endoscopic 
retrograde pancreatography: When should we do it? World J 




Endoscopic retrograde cholangiopancreatography 
(ERCP) is an invasive procedure that provides radiological 
visualization of the detailed structure and the patho­
logical changes of the biliary tree and pancreatic ducts 
by injection of contrast agent into the common bile 
duct (CBD) and the main pancreatic duct (MPD). Since 
its development in 1968, it has become a widely used 
and accurate imaging modality in the diagnosis of 
pancreatobiliary diseases[1]. Since the introduction of 
endoscopic sphincterotomy in 1974[2], ERCP has become 
the most important minimal invasive treatment method 
for various biliary and pancreatic diseases including 
bile duct or pancreatic duct stones (choledocholithiasis 
or wirsungolithiasis), benign and malignant biliary 
and pancreatic duct obstructions. Recently ERCP has 
transformed from a diagnostic method to an almost 
exclusively therapeutic procedure due to the widesp­
read availability of noninvasive cross­section imaging 
techniques such as abdominal ultrasound (AUS), 
computed tomography (CT), magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic 
ultrasound (EUS)[3]. Numerous studies emphasize the 
disadvantages of ERCP such as post­ERCP complications 
and the burden to patients. In a meta­analysis of 21 
prospective trials the incidence of mild­to­moderate 
complications reached 5.17%, and that of severe events 
up to 1.67%[4] (Table 1). Post­ERCP pancreatitis (PEP) 
is the most frequent complication with approximately 
3.5% but its incidence ranges widely (1.6%­15.7%) 
depending on the patient selection and the definition of 
pancreatitis[5­7]. Pancreatic duct injection substantially 
increased the risk of PEP, therefore the role of diagnostic 
endoscopic pancreatography (ERP) gradually decreased. 
International guidelines recommend ERCP only in 
cases where biliary intervention is required[3­8], but the 
indication of ERP is not clearly defined. According to 
the current guidelines routine rectal administration of 
100 mg diclofenac or indomethacin immediately before 
or after ERCP is strongly recommended to prevent 
PEP. In patients with MPD filling and increased patient 
or procedure related risk factors for PEP temporary 
application of prophylactic small caliber pancreatic 
stents is also recommended to reduce the risk of severe 
PEP[9]. 
The aim of this article is to systematically review 
the literature dealing with the diagnostic yield of ERP 
in various pancreatic diseases, and to define the 
principles and indications of ERP depending on the 
recommendations of international guidelines and the 
opinion of Hungarian experts (Tables 2 and 3) .
PaNCReas DIvIsUm
Pancreas divisum (PD) is the most common congenital 
anomaly of the pancreas in which the dorsal and 
ventral pancreatic duct drain separately into the 
duodenum. Recently ERP has been the gold standard 
imaging modality for the diagnosis of PD due to its 
high diagnostic accuracy[10,11], but the rate of complete 
pancreatography and the success of minor papilla 
cannulation significantly influence the sensitivity of 
ERP[12] (Figure 1). The high rate of complications is the 
greatest disadvantage of ERP, therefore noninvasive 
procedures, such as MRCP and EUS are increasingly 
spreading worldwide in this indication as well. Sensi­
tivity and specificity of MRCP in the detection of PD 
is 52%­73.3% and 96.8%­97%, and the diagnostic 
accuracy can further be improved with the use of 
secretin stimulation (73.3%­86% and 97%)[13,14] (Figure 
2). A comparison study carried out by Lai et al[15]. has 
shown that adequate evaluation of the pancreatic duct 
by EUS is possible in 78% of cases, and the sensitivity, 
specificity, and positive and negative predictive values 
for EUS are 95%, 97%, 86%, and 99%. 
ERP has an important therapeutic role in the endo­
scopic treatment (including minor papillotomy with 
or without pancreatic duct stenting) of patients with 
symptomatic PD. There is no prospective randomized 
controlled trial comparing endoscopic and surgical 
therapy, but previous retrospective studies could not 
detect any differences between the pooled overall 
response rates of the two treatment groups (endoscopic 
vs surgical treatment 54.3­79.2 vs 51.4­83.3 depending 
on the indication)[16]. 
aCUTe PaNCReaTITIs
The importance of ERCP in the identification of the 
etiology of acute pancreatitis (AP) has rapidly decreased 
in the recent decades due to the widespread availability 
of noninvasive imaging modalities[17]. The diagnosis 
of uncomplicated AP is mainly based on the clinical 
symptoms, elevated serum levels of pancreatic enzymes 
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Mild to moderate Severe Death
  Pancreatitis 3.07% 0.40% 0.11%
  Bleeding 0.95% 0.39% 0.05%
  Perforation 0.60% 0.06%
  Infection 1.15% 0.28% 0.11%
  Total 5.17% 1.67% 0.33%
Table 1  Frequency of procedure related complications of 
endoscopic retrograde pancreatography (6.85%) depending 
of the results of endoscopic retrograde pancreatography[4]
(amylase, lipase) and the morphological changes in the 
pancreas on the AUS, CT or MRI images[18]. Therapeutic 
ERCP with biliary sphincterotomy and removal of 
CBD stones can effectively improve the outcome, and 
according to the recent international guidelines it is 
indicated in acute biliary pancreatitis within 72 h, if 
noninvasive examinations prove the presence of acute 
cholangitis or raise the suspicion of CBD obstruction in 
association with acute pancreatitis[19,20]. On the contrary, 
failed biliary cannulation and repeated MPD filling in 
patients with acute biliary pancreatitis may worsen the 
overall outcome and therefore some data suggest that 
small caliber prophylactic pancreatic stents may be 
applied as a bridging procedure to prevent complications 
in this group of patients[21]. 
In 10%­15% of patients with recurrent acute 
pancreatitis if the complete noninvasive diagnostic 
evaluation could not reveal the exact cause and etiology, 
and as a consequence the diagnosis of “idiopathic” 
acute pancreatitis may arise. Therefore in patients with 
idiopathic acute pancreatitis, after the cessation of an 
acute inflammatory attack an ERCP with biliary and/or 
pancreatic sphincter of Oddi manometry, an endoscopic 
ultrasound, and secretin enhanced MRCP may leads 
to a diagnosis of biliary microlithiasis, sphincter of 
Oddi dysfunction, PD, cystic fibrosis, a choledochocele, 
annular pancreas, an anomalous pancreatobiliary 
junction, small pancreatobiliary tumors, or early stage 
of chronic pancreatitis[22,23]. 
ChRONIC PaNCReaTITIs
Chronic pancreatitis (CP) is a progressive fibroin­
flammatory disorder with irreversible destruction of 
the pancreatic parenchyma and ducts. Frequently the 
complications, such as bile duct stenosis, obstructive 
jaundice, diabetes mellitus or malabsorption call the 
attention for the presence of the disease[24]. In advan­
ced stages the recognition of parenchymal fibrosis 
and moreover calcification is relatively easy with AUS, 
CT, MRI and EUS, and typical ductal alterations with 
ERCP or MRCP[25]. The early recognition of CP and its 
differentiation from pancreatic cancer (PC) sometimes 
represents a real diagnostic challenge[26]. Currently 
ERCP has been replaced by EUS (especially with 
elastography), MRI, CT, and MRCP in the early diagnosis 
of CP. However, ERCP plays an essential role in the more 
precise identification of complications such as obstructive 
jaundice, pancreatic stones, MPD strictures, chronic 
abdominal pain, and also gives the opportunity for the 
minimally invasive treatment (pancreatic sphincterotomy 
or balloon dilatation, pancreatic duct stenting, etc.)[27] 
(Figure 3). The European Society of Gastroenterology 
recommends the endoscopic treatment as the first-line 
therapy for painful uncomplicated CP, and highlights its 
effectivity in the management of obstructive jaundice 
and pancreatic stones associated with CP[3] (Figures 
4 and 5). In cases of complicated CP the long­term 
efficacy of surgical intervention is superior to endoscopy 
in most patients[28,29]. Despite the fact, that repeated 
pancreatography is usually necessary during the 
endoscopic intervention of the pancreatic duct, the risk 
of PEP is significantly reduced in CP as compared to the 
general population. However, the role of ERP as first 
examination in the diagnosis of suspected complicated 
CP is questionable[6]. Therefore, in our clinical practice, 
we perform ERCP in CP patients only in case of chronic 
pancreatic pain and suspected MPD obstruction (stricture 
with prestenotic dilatation) based on MRCP or EUS. In 
these patients, pancreatic sphincterotomy, pancreatic 
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Indicated Slightly indicated Not indicated Description
  Pancreas divisum 83.6% 16.7%      0% During therapeutic intervention
  Acute pancreatitis 16.7%     50% 33.3% Recurrent "idiopathic" acute pancreatitis
  Chronic pancreatitis 83.3% 16.7%      0% Complicated chronic pancreatitis (MPD stricture, pancreatic duct stones, 
chronic abdominal pain, obstructive jaundice)
  Autoimmune pancreatitis 66.7% 33.3%      0% Suspicion of autoimmune pancreatitis which has not identified by 
noninvasive imaging techniques
  Pancreatic neoplasia      0%     50%    50% Suspicion of pancreatic neoplasia with obstructive jaundice
  Pancreatic cystic neoplasia      0% 16.7% 83.3% In case of IPMN ERP associated with high risk of complications
Pancreatic cysts and pseudocysts generally do not communicate with the 
pancreatic duct therefore the ERP cannot identify them
  Pancreatic injury   100%       0%      0% Suspicion of pancreatic ductal injury in stable patients
Suspicion of pancreatic fistula
Suspicion of fistula formation
  Postoperative pancreatic fistula   100%       0%      0%
Table 2  Indication of endoscopic retrograde pancreatography based on the opinion of Hungarian experts
ERP: Endoscopic pancreatography; MDP: Main pancreatic duct; IPMN: Intraductal papillary mucinous neoplasms.
  Indicated Not indicated Description
  50% 50% ERP may help differentiate between 
cholangiocarcinoma and pancreatic 
illnesses
Table 3  Indication of endoscopic retrograde pancreatography 
in the case of suprapapillary bile duct stenosis based on the 
opinion of Hungarian experts
ERP: Endoscopic pancreatography.
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focal mass is found, which can lead to false diagnosis 
of pancreatic malignancy[36,37]. Ductal imaging, ERP 
and MRCP may show a long, narrow ductal stricture 
(greater than one­third the length of the MPD) or 
multiple, non­continuous strictures without marked 
upstream dilation, and side branches arising from the 
stricture[38­40]. However, given that ERCP is an invasive 
method which debit the patient and can cause adverse 
effects (pancreatitis, bleeding), the noninvasive 
MRCP is becoming the first choice examination for 
pancreatobiliary diseases. Previous comparison 
studies have shown that MRCP is less sensitive in the 
differentiation of focal form of AIP and PC, therefore 
cannot completely replace ERCP for the diagnostic 
evaluation of AIP[41,42]. The multicenter study carried out 
by Suguma et al[43]. has highlighted the ability of ERP to 
diagnose AIP based on ERP feature alone is limited, but 
taken together with clinical symptoms, serology and/or 
histology it can be useful.
PaNCReaTIC NeOPLasIa
Previously ERCP was the gold standard in the diagnosis 
of PC. Localized MPD stenosis with focal ductal branch 
dilation and with distal dilation of MPD (“double duct” 
sign) were the most frequently detectable morphological 
stricture dilatation and multiple plastic or self­expanding 
metal stenting during ERP proved to be useful to 
achieve long term symptomatic improvement.
aUTOImmUNe PaNCReaTITIs
Autoimmune pancreatitis (AIP) is an uncommon inflam-
matory disorder of the pancreas with a presumed 
autoimmune etiology[30]. It may present with a wide 
variety of clinical and morphological features including 
painless obstructive jaundice, asymptomatic focal mass 
or diffuse enlargement of the pancreas which mimic 
PC[31]. The diagnosis of AIP requires a multidisciplinary 
approach including imaging studies, histology, serology, 
assessment of other organ involvement and the thera­
peutic response to steroid treatment[32,33]. There were 
differences in the diagnostic approach and the tech­
niques used between different countries. For instance, 
ERP is usually ignored in Western counties to avoid PEP 
in contrast to Japan where this examination is usually 
performed[34]. The correct diagnosis requires detailed 
information equally about the pancreatic parenchyma 
and ducts. In typical cases of AIP a diffusely enlarged 
or “sausage shaped” pancreas with featureless borders 
and/or loss of lobular architecture can be detected 
with AUS, CT and MRI[35]. In 30%­40% of the cases 
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Figure 1  Endoscopic retrograde pancreatography image: Pancreas 
divisum with minor papilla cannulation.
Figure 3  Endoscopic pancreatography image: Chronic pancreatitis with 
Wirsungolithiasis.
Figure 2  Secretin enhanced magnetic resonance cholangiopancreatography 
image: Pancreatic divisum and juxtapapillary diverticulum.
Figure 4  Endoscopic pancreatography image: Pancreatic duct stenosis 
with prestenotic dilatation after preventive pancreatic stent implantation.
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The pathognomonic characteristic of IPMN is the 
gaping orifice of Vater papilla with thick mucus oozing 
(fish mouth papilla)[51]. The international consensus 
guidelines do not recommend the routine ERP for the 
morphological and cytological diagnosis of IPMN (fluid 
sampling or brushing of MPD) due to the invasiveness 
of the procedure and the high risk of complications. 
Currently MRCP, EUS and EUS­guided sampling are 
most preferred[52,53]. The other malignant cyst type 
and the pancreatic pseudocysts generally do not 
communicate with the pancreatic duct, therefore the 
ERP cannot identify them.
PaNCReaTIC INjURy
Blunt pancreatic trauma can frequently lead to acute 
pancreatitis with or without MPD disruption. Pancreatic 
injuries caused by blunt abdominal trauma are 
relatively rare with an overall incidence of 0.2%­12%[54]. 
Pancreatic injury occurs as a result of the traumatic 
compression of the pancreas between the vertebral 
column and the anterior abdominal wall. Pancreatic 
injury is more common in children and young adults 
because of decreased protective intra­abdominal fat. 
CT is the primary imaging modality of choice in patients 
with blunt abdominal trauma, with the sensitivity for 
pancreatic parenchymal injury between 67%­85%[55]. 
Although pancreatic ductal injury can frequently be 
detected with non­invasive MRCP, ERCP is the most 
accurate diagnostic tool for the assessment of ductal 
injury[56]. Besides, it can also provide endoscopic 
treatment. Delays in ERCP have led to significantly 
higher complication rates[57]. Although ERCP is the most 
useful procedure for the diagnosis of pancreatic ductal 
injury in stable patients, surgery should be considered 
without hesitation if the patient’s condition is unstable. 
Recently, some case series proved that pancreatic duct 
plastic stent placement with and without pancreatic 
sphincterotomy can be an effective endoscopic therapy 
in resolving pancreatic duct disruption and preventing 
chronic fistula formation[58]. Although stent implantation 
can improve the clinical condition and resolve fistula and 
pseudocyst, stent induced ductal stricture is a major 
changes[44,45]. The current role of ERCP is therapeutic 
rather than diagnostic. In cases of inoperable locally 
advanced and metastatic pancreatic malignancy 
the development of obstructive jaundice constitutes 
an absolute indication of ERCP[46]. Malignant biliary 
stenosis may be treated with plastic, but preferably 
with self­expandable metallic stent implantation[3]. 
Pancreatography, ERCP­guided brush cytological 
sampling and/or biopsy of the pancreatic duct may 
be useful to prove malignancy, but EUS­guided fine 
needle aspiration (EUS-FNA) is the first-choice sampling 
procedure in suspected unresectable pancreatic solid 
and cystic lesions due to minimal invasiveness, lower 
complication rate and higher sensitivity compared to 
ERCP sampling[47]. A meta­analysis performed by Li 
et al[48]. showed that ERCP combined with EUS was 
associated with a high diagnostic yield compared 
to ERCP or EUS alone, but the complete length of 
procedures substantially increased, however, it can be 
reduced if the two examination are performed under 
the same sedation, but the rate of complication not 
changed[49]. 
CysTIC PaNCReaTIC LesIONs
Cystic pancreatic lesions represent a great diagnostic 
problem because of the morphological similarities 
between benign and malignant cysts and because of 
the possibility of malignant transformation[50] and the 
increasing number of the detected lesions due to the 
improvement of the abdominal imaging modalities 
and their availabilities. The differentiation between 
the four types of pancreatic cystic neoplasms (PCN) 
substantially may influence the therapeutic approach. 
Serous cystadenomas (SCA) and solid pseudopapillary 
neoplasms (SPN) are associated with lower malignant 
potential compared to intraductal papillary mucinous 
neoplasms (IPMN) and mucinous cystic neoplasms 
(MCN). Previously ERP was the gold standard diagnostic 
procedure in the identification and classification of IPMN. 
Diffuse or segmental dilation of the MPD or its side 
branches connected to the cyst can be recognized on 
the ERP images, with no other cause of the dilatation. 
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Figure 5  Endoscopic pancreatography image: Bile duct and pancreatic 
duct stent implantation in chronic pancreatitis.
Figure 6  Endoscopic retrograde pancreatography image: Postoperative 
pancreaticopleural fistula.
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disorders, including idiopathic acute recurrent pancrea­
titis, chronic pancreatitis, pancreatic ductal injuries 
and fistula formation, pancreatic cystic neoplasms and 
early pancreatic cancer. However, before performing 
ERP, endoscopists should carefully evaluate the extent 
of the clinically necessary pancreatogram, if there any, 
to establish the diagnosis. Increasingly widespread 
application of noninvasive methods for the diagnosis 
of pancreatobiliary diseases (such as MRCP and 
EUS), and less frequent use of diagnostic ERP could 
dramatically decrease post­ERCP complications. In 
contrast, pancreatic interventional endoscopic proce­
dures, such as pancreatic sphincterotomy, dilatations 
and pancreatic stent implantation are necessitates for 
complete pancreatic ductal contrast filling and analysis 
of digitally enhanced pancreatogram with fluoroscopy 
to completely understand the anatomy and intraductal 
pathology before the initiation of endoscopic therapy. 
In case of distal biliary obstruction, when the non­
invasive imaging modalities are available we do not 
recommend the filling of pancreatic duct, selective biliary 
drainage is proposed. ERP should be considered in case 
of suspected pancreatic ductal abnormalities, such as 
pancreatic injury, fistula or congenital malformation, and 
when pancreatic ductal intervention is necessary.
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POsTOPeRaTIve PaNCReaTIC FIsTULa 
Postoperative pancreatic fistula (POPF) formation 
is a frequent and severe complication of pancreatic 
surgery[59,60]. Its incidence ranges from 2% to 51% 
depending on the definition used. POPF was defined 
by International Study Group on Pancreatic Fistula as a 
measurable drain output on or after postoperative day 
3 with an amylase content greater than 3 times the 
serum amylase activity[61]. In the early postoperative 
phase the upper abdominal discomfort associated with 
fever, tachycardia, slower recovery and persistently 
high drain output raises the suspicion of postoperative 
complication, such as pancreatic fistula (Figure 6). The 
amylase level of drain fluid is extremely elevated in a 
typical case[62]. ERCP and MRCP are the two most widely 
used imaging modality in the confirmation of POPF with 
high diagnostic accuracy. In case of pancreaticopleural 
fistula their sensitivity may reach to 78% and 80%[63]. 
Recently ERCP was the most preferred investigation for 
confirming the diagnosis of POPF, but its use is reduced 
due to invasive nature and elevated risk of infective 
complications arising from fistula filling. However, it has 
the advantage of direct visualization of MPD and precise 
location of fistula, and the ability to simultaneously 
perform endoscopic therapeutic maneuvers[64]. 
PaNCReaTObILIaRy maLjUNCTION
Pancreatobiliary maljunction (PBM) is a rare congenital 
malformation in which the CBD and the pancreatic duct 
are united outside the duodenal wall with or without 
dilation of CBD[65]. The sphincter of oddi is located in 
the distal part of the common channel, therefore it 
cannot properly regulate the outflow of biliopancreatic 
juice, resulting regurgitation of bile into the MPD and 
pancreatic juice into the CBD. The elevated intraductal 
pressure often causes dilatation of CBD, and the chronic 
biliopancreatic reflux increases the risk of development 
of malignancy. The diagnosis of PBM is based on the 
identification of the anomalous union between the 
pancreatic and bile ducts by ERCP, MRCP, EUS or intraduc­
tal ultrasound. ERCP is the most accurate imaging 
method, and it provides an opportunity for the biliary 
intervention (biliary stone extraction, stent implantation) 
and bile sampling as well. High biliary levels of pancreatic 
enzymes are suggestive of regurgitation of pancreatic 
juice into the common bile duct[66]. In atypical PBM 
cases with relatively short common channel, the diag­
nostic accuracy of MRCP and EUS is lower, but they 
are very effective in the detection of PBM associated 
pancreatobiliary cancers at an early stage[67].
CONCLUsION
ERP is still one of the most accurate diagnostic proce­
dures in patients with suspected pancreatic ductal 
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